X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

OPINION & ORDER Defendants Alkermes plc (“Alkermes”), Richard F. Pops, its Chief Executive Officer, and James M. Frates, its Chief Financial Officer, move to dismiss the Second Amended Complaint (the “Complaint”) under Rule 12(b)(6) of the Federal Rules of Civil Procedure. Lead Plaintiff Local 731 I.B. of T. Private Scavenger and Garage Attendants Pension Trust Fund (“Local 731″) moves to strike various exhibits appended to Defendants’ motion. For the reasons that follow, Local 731′s motion to strike is granted in part and denied in part, and Defendants’ motion to dismiss is granted.BACKGROUNDThe allegations in the Complaint are presumed true for purposes of this motion. Alkermes is a global pharmaceutical company that markets and sells a product trade-named Vivitrol, an injectable, extended-release version of an opioid dependence medication called naltrexone. This securities fraud class action concerns statements that Defendants made touting Vivitrol’s sales growth and its effectiveness in treating opioid dependence. Local 731 claims that while Defendants crafted a narrative of organic, word-of-mouth growth in SEC filings and on investor conference calls, they concealed from investors a calculated and sustained campaign to market Vivitrol.Starting in June 2017, the truth began to emerge through a steady cascade of news articles that shed a critical light on Alkermes’ sales practices, academic studies that reached tepid conclusions as to Vivitrol’s relative effectiveness, and revelations of governmental scrutiny of Vivitrol. Based on a progressive decline in Alkermes’ stock price, plaintiffs assert claims against all Defendants for violations of Section 10(b) of the Securities Exchange Act and Rule 10b-5 promulgated thereunder, as well as Section 20(a) claims against Pops and Frates.I. Opioid Dependence TreatmentsSince the 1980s, naltrexone has existed to treat opioid dependence. (Second Amended Complaint, ECF No. 34 (“Compl.”),

23-26.) In particular, naltrexone works by competing for the receptors in the brain that cause the “high” that one experiences from using opioids. However, several aspects of naltrexone contributed to its sparse use by the medical community. First, patients must endure a days-long detoxification process before beginning treatment. Second, naltrexone only provides a brief period of relief from opioid cravings and must be taken every day. Third, because it does not completely block the targeted brain receptors, its effects may be overcome with a sufficiently large quantity of opioids.Alkermes sought to improve on naltrexone by developing Vivitrol, an injectable version of naltrexone that extends relief from opioid cravings for 28 days. (Compl.

 
Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.

More From ALM

Premium Subscription

With this subscription you will receive unlimited access to high quality, online, on-demand premium content from well-respected faculty in the legal industry. This is perfect for attorneys licensed in multiple jurisdictions or for attorneys that have fulfilled their CLE requirement but need to access resourceful information for their practice areas.
View Now

Team Accounts

Our Team Account subscription service is for legal teams of four or more attorneys. Each attorney is granted unlimited access to high quality, on-demand premium content from well-respected faculty in the legal industry along with administrative access to easily manage CLE for the entire team.
View Now

Bundle Subscriptions

Gain access to some of the most knowledgeable and experienced attorneys with our 2 bundle options! Our Compliance bundles are curated by CLE Counselors and include current legal topics and challenges within the industry. Our second option allows you to build your bundle and strategically select the content that pertains to your needs. Both options are priced the same.
View Now

New York Legal Awards 2021

October 13, 2021
New York, NY

The New York Law Journal honors attorneys and judges who have made a remarkable difference in the legal profession in New York.


Register

General Counsel Conference East 2021

September 22, 2021 - September 23, 2021
New York, NY

GCC East addresses General Counsel trends in regulatory, data protection, tech management, legal operations, and leadership.


Register

New Jersey Legal Awards 2021

September 23, 2021
Virtual, NJ

New Jersey Law Journal honors lawyers leaving a mark on the legal community in New Jersey with their dedication to the profession.


Register

Corporate Transactional Associate

Hackensack, New Jersey, United States

COLE SCHOTZ P.C. CORPORATE/TRANSACTIONAL ASSOCIATE- DELAWARE, FLORIDA, MARYLAND, NEW JERSEY, NEW YORK OR TEXAS OFFICES:   Promi...


Apply Now ›

Litigation Attorney - Atlanta, Georgia

Atlanta, Georgia, United States

Sole practitioner seeks attorney for complex litigation. Hours are flexible and can be part-time. Must be able to work remote...


Apply Now ›

Trusts & Estates Administrative Paralegal

Hackensack, New Jersey, United States

COLE SCHOTZ P.C. TRUSTS & ESTATES ADMINISTRATION PARALEGAL- NEW JERSEY, NEW YORK OR FLORIDA OFFICE: Prominent NJ based law firm with m...


Apply Now ›

JAVERBAUM WURGAFT HICKS

09/20/2021
NJLJ Web

JAVERBAUM WURGAFT HICKS mourn the passing of our Co-Founding Partner, collegue, and friend.


View Announcement ›

BARTON GILMAN LLP

09/14/2021
CLT Web

Barton Gilman Expands Into Connecticut


View Announcement ›

BARTON GILMAN LLP

09/14/2021
TLI Web

Barton Gilman LLP is excited to announce that its expansion into Philadelphia


View Announcement ›